Bibliographic Details
| Title: |
Interacción de linezolid con rifampicina: a propósito de un caso. |
| Alternate Title: |
Pharmacokinetic interaction between linezolid and rifampicin: A case report. |
| Authors: |
Fernández-Vázquez, Ana1 anafernandez.fh@gmail.com, Ayala-Álvarez-Canal, Juan1, García González, David1, Sáez-Villafañe, Mónica1, Dios-Díez, Paula1, José Ortiz-de-Urbina-González, Juan1 |
| Source: |
Revista Española de Quimioterapia. feb2026, Vol. 39 Issue 1, p76-79. 4p. |
| Subjects: |
LINEZOLID, RIFAMPIN, DRUG monitoring, METHICILLIN-resistant staphylococcus aureus, DRUG dosage, DRUG side effects, DRUG interactions |
| Abstract (English): |
The article focuses on the pharmacokinetic interaction between linezolid and rifampicin, highlighting its relevance in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. It presents the case of a 60-year-old woman with a surgically treated fracture who developed an infection and was treated with linezolid and rifampicin. Although the interaction between the two drugs is known, it emphasizes the lack of established dosing strategies and the importance of therapeutic monitoring to ensure treatment efficacy and minimize the risk of toxicity. Follow-up of the case showed a favorable clinical evolution without significant adverse reactions. [Extracted from the article] |
| Abstract (Spanish): |
El artículo se centra en la interacción farmacocinética entre linezolid y rifampicina, destacando su relevancia en el tratamiento de infecciones por Staphylococcus aureus resistente a meticilina (SARM). Se presenta el caso de una mujer de 60 años con una fractura tratada quirúrgicamente, que desarrolló una infección y fue tratada con linezolid y rifampicina. A pesar de que la interacción entre ambos fármacos es conocida, se subraya la falta de estrategias de dosificación establecidas y la importancia de la monitorización terapéutica para asegurar la eficacia del tratamiento y minimizar el riesgo de toxicidad. El seguimiento del caso mostró una evolución clínica favorable sin reacciones adversas significativas. [Extracted from the article] |
|
Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
